GlassScriptPhysician profile
Chris Olmstead
NPI 1134817596
$3,258.36
in general payments reported to CMS, 2019-2025
31 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $663 · 2024: $1,039 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.15 | 2023-2025 | |
| Novo Nordisk INC | $341.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $310.20 | 2023-2025 | |
| Lilly USA, LLC | $303.17 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $273.16 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Corcept Therapeutics | $190.22 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $185.13 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $181.94 | 2024-2025 | Voquezna |
| Myriad Women'S Health, INC. | $159.21 | 2023 | Myrisk |
| Shield Therapeutics INC | $100.90 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.60 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.27 | 2023-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $64.16 | 2023-2024 | Rexulti |
| Cranial Technologies, INC | $52.65 | 2024-2025 | Doc Band |
| Medtronic, INC. | $44.47 | 2024-2025 | Intellis Adaptivestim, Venaseal |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.24 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.33 | 2023-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $40.27 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $38.02 | 2025 | Jornay Pm |
| Amgen INC. | $27.33 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $25.91 | 2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $25.08 | 2024 | |
| Gilead Sciences, INC. | $23.26 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2024 | |
| Seqirus USA INC | $20.95 | 2024 | Fluad, Flucelvax |
| Azurity Pharmaceuticals, INC. | $20.43 | 2025 | Horizant |
| Viatris Specialty LLC | $17.47 | 2025 | Yupelri |
| Qiagen, LLC | $16.07 | 2024 | |
| Optumhealth Care Solutions, LLC | $14.35 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Corium, LLC | $14.02 | 2024 | Azstarys |
| Merck Sharp & Dohme LLC | $13.24 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Olmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.